50
Table 29. Ten Most Common Co-Occurring Chronic
Conditions Among Medicare Beneficiaries With HF
(N=4,947,918), 2011
Beneficiaries Age ≥65 y
(N = 4,376,150)
a
Beneficiaries Age <65 y
(N = 571,768)
b
N % N %
Hypertension 3,685,373 84.2 Hypertension 461,235 80.7
Ischemic heart
disease
3,145,718 71.9 Ischemic heart
disease
365,889 64.0
Hyperlipidemia 2,623,601 60.0 Diabetes 338,687 59.2
Anemia 2,200,674 50.3 Hyperlipidemia 325,498 56.9
Diabetes 2,027,875 46.3 Anemia 284,102 49.7
Arthritis 1,901,447 43.5 Chronic kidney
disease
257,015 45.0
Chronic kidney
disease
1,851,812 42.3 Depression 207,082 36.2
COPD 1,311,118 30.0 Arthritis 201,964 35.3
AF 1,247,748 28.5 COPD 191,016 33.4
Alzheimer
disease/dementia
1,207,704 27.6 Asthma 88,816 15.5
a
Mean number of conditions, 6.1; median, 6.
b
Mean number of conditions, 5.5; median, 5.
Data source: Centers for Medicare & Medicaid Services administrative claims data, January 2011 to
December 2011, from the Chronic Condition Warehouse (CCW), ccwdata.org.
Other Comorbidities
Table 28. Anemia: Recommendations (2017)
COR
LOE Recommendations
IIb B-R In patients with NYHA class II and III HF and iron deficiency
(ferritin <100 ng/mL or 100–300 ng/mL if transferrin saturation
is <20%), intravenous iron replacement might be reasonable to
improve functional status and QoL.
III: No
Benefit
B-R In patients with HF and anemia, erythropoietin-stimulating agents
should not be used to improve morbidity and mortality.
Treatment
